Published in Am J Pathol on November 01, 2005
Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med (2009) 2.93
Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proc Natl Acad Sci U S A (2009) 2.22
Anthrax toxins cooperatively inhibit endocytic recycling by the Rab11/Sec15 exocyst. Nature (2010) 1.95
Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats. Crit Care Med (2009) 1.60
Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice. Cell Host Microbe (2010) 1.51
Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax. Infect Immun (2006) 1.45
Sepsis and pathophysiology of anthrax in a nonhuman primate model. Am J Pathol (2006) 1.39
Role of the protective antigen octamer in the molecular mechanism of anthrax lethal toxin stabilization in plasma. J Mol Biol (2010) 1.36
Anthrax toxin receptor 2-dependent lethal toxin killing in vivo. PLoS Pathog (2006) 1.34
Anthrax lethal and edema toxins in anthrax pathogenesis. Trends Microbiol (2014) 1.33
Anthrax toxins induce shock in rats by depressed cardiac ventricular function. PLoS One (2007) 1.32
Key tissue targets responsible for anthrax-toxin-induced lethality. Nature (2013) 1.28
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun (2009) 1.22
A Bacillus anthracis strain deleted for six proteases serves as an effective host for production of recombinant proteins. Protein Expr Purif (2011) 1.21
Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines. J Infect Dis (2010) 1.19
Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax. Am J Pathol (2011) 1.16
The adenylyl cyclase activity of anthrax edema factor. Mol Aspects Med (2009) 1.15
New insights into the biological effects of anthrax toxins: linking cellular to organismal responses. Microbes Infect (2011) 1.14
Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding. Proc Natl Acad Sci U S A (2009) 1.14
Updating perspectives on the initiation of Bacillus anthracis growth and dissemination through its host. Infect Immun (2012) 1.10
Cell entry and cAMP imaging of anthrax edema toxin. EMBO J (2006) 1.09
Anthrax lethal toxin induces cell death-independent permeability in zebrafish vasculature. Proc Natl Acad Sci U S A (2008) 1.08
Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy. Am J Respir Crit Care Med (2006) 1.08
Clostridium sordellii lethal toxin kills mice by inducing a major increase in lung vascular permeability. Am J Pathol (2007) 1.06
Discriminating virulence mechanisms among Bacillus anthracis strains by using a murine subcutaneous infection model. Infect Immun (2008) 1.06
Contribution of lethal toxin and edema toxin to the pathogenesis of anthrax meningitis. Infect Immun (2011) 1.06
Anthrax and the inflammasome. Microbes Infect (2011) 1.06
Anthrax edema toxin sensitizes DBA/2J mice to lethal toxin. Infect Immun (2007) 1.01
Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge. J Infect Dis (2010) 1.01
Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax. Infect Immun (2012) 1.01
Anthrax lethal factor and edema factor act on conserved targets in Drosophila. Proc Natl Acad Sci U S A (2006) 1.00
Contributions of histamine, prostanoids, and neurokinins to edema elicited by edema toxin from Bacillus anthracis. Infect Immun (2007) 1.00
Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity. Vaccine (2011) 0.99
The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes. Infect Immun (2009) 0.99
Pathophysiology of anthrax. Front Biosci (Landmark Ed) (2009) 0.96
In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin. Antimicrob Agents Chemother (2008) 0.96
Anthrax lethal toxin suppresses murine cardiomyocyte contractile function and intracellular Ca2+ handling via a NADPH oxidase-dependent mechanism. PLoS One (2010) 0.96
Differential contribution of Bacillus anthracis toxins to pathogenicity in two animal models. Infect Immun (2012) 0.96
Transcriptional stimulation of anthrax toxin receptors by anthrax edema toxin and Bacillus anthracis Sterne spore. Microb Pathog (2007) 0.95
Role of purine biosynthesis in Bacillus anthracis pathogenesis and virulence. Infect Immun (2010) 0.95
The physiologic responses of Dutch belted rabbits infected with inhalational anthrax. Comp Med (2009) 0.95
Anthrax infection inhibits the AKT signaling involved in the E-cadherin-mediated adhesion of lung epithelial cells. FEMS Immunol Med Microbiol (2009) 0.94
Bacillus anthracis protease InhA increases blood-brain barrier permeability and contributes to cerebral hemorrhages. PLoS One (2011) 0.93
Noncapsulated toxinogenic Bacillus anthracis presents a specific growth and dissemination pattern in naive and protective antigen-immune mice. Infect Immun (2007) 0.92
Neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax. Infect Immun (2010) 0.91
Hemodynamic effects of anthrax toxins in the rabbit model and the cardiac pathology induced by lethal toxin. Toxins (Basel) (2011) 0.91
The receptors that mediate the direct lethality of anthrax toxin. Toxins (Basel) (2012) 0.91
Glycogen synthase kinase 3 activation is important for anthrax edema toxin-induced dendritic cell maturation and anthrax toxin receptor 2 expression in macrophages. Infect Immun (2011) 0.90
Anthrax edema toxin modulates PKA- and CREB-dependent signaling in two phases. PLoS One (2008) 0.90
Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors. Bioorg Med Chem (2009) 0.89
Cell cycle arrest induced by the bacterial adenylate cyclase toxins from Bacillus anthracis and Bordetella pertussis. Cell Microbiol (2010) 0.89
Histopathology in a murine model of anthrax. Int J Exp Pathol (2006) 0.88
Bacillus anthracis edema toxin suppresses human macrophage phagocytosis and cytoskeletal remodeling via the protein kinase A and exchange protein activated by cyclic AMP pathways. Infect Immun (2009) 0.88
Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob Agents Chemother (2007) 0.88
B. anthracis edema toxin increases cAMP levels and inhibits phenylephrine-stimulated contraction in a rat aortic ring model. Am J Physiol Heart Circ Physiol (2013) 0.88
Mouse monoclonal antibodies to anthrax edema factor protect against infection. Infect Immun (2011) 0.88
The potential contributions of lethal and edema toxins to the pathogenesis of anthrax associated shock. Toxins (Basel) (2011) 0.88
Small-molecule inhibitors of lethal factor protease activity protect against anthrax infection. Antimicrob Agents Chemother (2013) 0.87
The sepsis model: an emerging hypothesis for the lethality of inhalation anthrax. J Cell Mol Med (2013) 0.87
Cytoskeleton as an emerging target of anthrax toxins. Toxins (Basel) (2012) 0.86
In situ gastrointestinal protection against anthrax edema toxin by single-chain antibody fragment producing lactobacilli. BMC Biotechnol (2011) 0.86
Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax. Infect Immun (2008) 0.86
The effects of anthrax lethal toxin on host barrier function. Toxins (Basel) (2011) 0.86
Bacillus anthracis edema toxin activates nuclear glycogen synthase kinase 3beta. Infect Immun (2008) 0.85
Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin. Toxins (Basel) (2010) 0.84
Suppression of dendritic cell activation by anthrax lethal toxin and edema toxin depends on multiple factors including cell source, stimulus used, and function tested. DNA Cell Biol (2008) 0.84
Anthrax lethal toxin downregulates claudin-5 expression in human endothelial tight junctions. PLoS One (2013) 0.84
Cellular and physiological effects of anthrax exotoxin and its relevance to disease. Front Cell Infect Microbiol (2012) 0.84
Molecular determinants for a cardiovascular collapse in anthrax. Front Biosci (Elite Ed) (2014) 0.83
Anthrax SET protein: a potential virulence determinant that epigenetically represses NF-κB activation in infected macrophages. J Biol Chem (2013) 0.83
Transcriptional profiling of murine organ genes in response to infection with Bacillus anthracis Ames spores. Microb Pathog (2007) 0.82
Anthrax edema factor toxicity is strongly mediated by the N-end rule. PLoS One (2013) 0.82
Anthrax lethal toxin induces acute diastolic dysfunction in rats through disruption of the phospholamban signaling network. Int J Cardiol (2013) 0.82
Contributions of edema factor and protective antigen to the induction of protective immunity by Bacillus anthracis edema toxin as an intranasal adjuvant. J Immunol (2010) 0.81
The International Bacillus anthracis, B. cereus, and B. thuringiensis Conference, "Bacillus-ACT05". J Bacteriol (2006) 0.81
Anthrax edema toxin impairs clearance in mice. Infect Immun (2011) 0.81
Tumor Targeting and Drug Delivery by Anthrax Toxin. Toxins (Basel) (2016) 0.80
Bacillus anthracis-derived edema toxin (ET) counter-regulates movement of neutrophils and macromolecules through the endothelial paracellular pathway. BMC Microbiol (2012) 0.80
Targeted silencing of anthrax toxin receptors protects against anthrax toxins. J Biol Chem (2014) 0.79
Emergence of anthrax edema toxin as a master manipulator of macrophage and B cell functions. Toxins (Basel) (2010) 0.79
Immunization of mice with formalin-inactivated spores from avirulent Bacillus cereus strains provides significant protection from challenge with Bacillus anthracis Ames. Clin Vaccine Immunol (2012) 0.78
Pharmacophore selection and redesign of non-nucleotide inhibitors of anthrax edema factor. Toxins (Basel) (2012) 0.78
The case for developing consensus standards for research in microbial pathogenesis: Bacillus anthracis toxins as an example. Infect Immun (2009) 0.77
Structural basis of anthrax edema factor neutralization by a neutralizing antibody. Biochem Biophys Res Commun (2011) 0.77
Lethal factor, but not edema factor, is required to cause fatal anthrax in cynomolgus macaques after pulmonary spore challenge. Am J Pathol (2014) 0.77
Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin. Methods Mol Biol (2009) 0.77
The Ins and Outs of Anthrax Toxin. Toxins (Basel) (2016) 0.77
Bacterial Toxins as Pathogen Weapons Against Phagocytes. Front Microbiol (2016) 0.77
Alternative pre-approved and novel therapies for the treatment of anthrax. BMC Infect Dis (2016) 0.75
Global Metabolomic Analysis of a Mammalian Host Infected with Bacillus anthracis. Infect Immun (2015) 0.75
Defensive strategies of Bacillus anthracis that promote a fatal disease. Drug Discov Today Dis Mech (2007) 0.75
Diminished but Not Abolished Effect of Two His351 Mutants of Anthrax Edema Factor in a Murine Model. Toxins (Basel) (2016) 0.75
Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis (2001) 11.73
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science (1998) 10.53
Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A (1982) 10.36
Cholera. Lancet (2004) 10.22
Anthrax toxin. Annu Rev Cell Dev Biol (2003) 5.92
Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A (1993) 5.39
Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun (1991) 4.17
ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc Natl Acad Sci U S A (1998) 4.04
Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem J (2000) 3.83
Purification of factor I and recognition of a third factor of the anthrax toxin. J Gen Microbiol (1961) 3.75
Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature (2002) 3.67
Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest (2003) 3.57
Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA (2002) 3.26
Chemokines in cutaneous wound healing. J Leukoc Biol (2001) 3.19
Neuroendocrine regulation of immunity. Annu Rev Immunol (2001) 3.11
Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) (1999) 2.71
2. Cytokines and chemokines. J Allergy Clin Immunol (2003) 2.54
Plasmid-associated virulence factors of non-toxigenic (pX01-) Bacillus anthracis. Microb Pathog (1991) 2.38
Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest (1995) 2.28
Bordatella pertussis adenylate cyclase: a toxin with multiple talents. Trends Microbiol (1999) 2.22
Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect Immun (2004) 2.14
Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 K(ATP) channels. J Clin Invest (2002) 2.11
Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol (2003) 2.11
Quantitative pathology of inhalational anthrax I: quantitative microscopic findings. Mod Pathol (2001) 2.10
Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab Invest (2003) 2.03
Inhalational anthrax: epidemiology, diagnosis, and management. Chest (1999) 1.97
Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity. Infect Immun (2004) 1.95
Expression and characterization of calmodulin-activated (type I) adenylylcyclase. J Biol Chem (1991) 1.94
Role of toxin functional domains in anthrax pathogenesis. Infect Immun (2000) 1.93
Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. Mol Med (1998) 1.64
Anthrax toxins. Rev Physiol Biochem Pharmacol (2004) 1.60
Introduction: anthrax history, disease and ecology. Curr Top Microbiol Immunol (2002) 1.57
Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP. Infect Immun (1994) 1.57
Anthrax toxin: a tripartite lethal combination. FEBS Lett (2002) 1.54
Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 1.46
Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J Biol Chem (2003) 1.43
Cushing, cortisol, and cardiovascular disease. Hypertension (2000) 1.21
Ltx1, a mouse locus that influences the susceptibility of macrophages to cytolysis caused by intoxication with Bacillus anthracis lethal factor, maps to chromosome 11. Mol Microbiol (1998) 1.20
Induction of neutrophilic granulocytosis in mice by administration of purified human native granulocyte colony-stimulating factor (G-CSF). Biochem Biophys Res Commun (1987) 1.17
Cross-talk of opioid peptide receptor and beta-adrenergic receptor signalling in the heart. Cardiovasc Res (2004) 1.11
Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis (2003) 1.10
G-CSF: function and modes of action (Review). Int J Mol Med (2002) 1.08
The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. J Pathol (2003) 1.07
Contribution of sex and genetics to neuroendocrine adaptation to stress in mice. Psychoneuroendocrinology (1998) 1.05
Comparison of adrenocortical zonation in C57BL/6J and DDD mice. Exp Anim (1995) 0.89
Adenosine signalling pathways in the pituitary gland: one ligand, multiple receptors. J Endocrinol (2003) 0.88
Inhalational anthrax: radiologic and pathologic findings in two cases. AJR Am J Roentgenol (2003) 0.87
Sensitivity of bone to glucocorticoids. Clin Sci (Lond) (2004) 0.87
Possible involvement of cyclic adenosine 3':5'-monophosphate in the genesis of catecholamine-induced tachycardia in isolated rabbit sinoatrial node. J Pharmacol Exp Ther (1977) 0.84
Cyclic AMP increases endogenous granulocyte colony-stimulating factor formation in monocytes and THP-1 macrophages despite attenuated TNF-alpha formation. Eur J Immunol (2003) 0.83
Inferior vena cava thrombosis: a mechanism of posttraumatic adrenal hemorrhage. AJR Am J Roentgenol (2001) 0.80
Nontraditional aspects of aldosterone physiology. Am J Physiol Endocrinol Metab (2001) 0.80
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle (2008) 4.95
Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol (2003) 3.97
Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature (2002) 3.67
Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol (2005) 3.59
Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest (2003) 3.57
Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature (2004) 3.36
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature (2006) 3.21
Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med (2009) 2.93
Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. Nat Med (2002) 2.90
The roles of anthrax toxin in pathogenesis. Curr Opin Microbiol (2004) 2.89
Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature (2003) 2.83
Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol (2002) 2.77
Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J Biol Chem (2002) 2.76
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther (2011) 2.75
Spontaneous coronary vasospasm in KATP mutant mice arises from a smooth muscle-extrinsic process. Circ Res (2006) 2.64
Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol (2004) 2.58
Phylogeography of the fungal pathogen Histoplasma capsulatum. Mol Ecol (2003) 2.44
Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature (2012) 2.41
The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin. Cell (2006) 2.40
Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway. J Cell Biol (2004) 2.31
The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res (2004) 2.29
Nesprin-1alpha self-associates and binds directly to emerin and lamin A in vitro. FEBS Lett (2002) 2.24
Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proc Natl Acad Sci U S A (2009) 2.22
Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem (2003) 2.19
Receptor palmitoylation and ubiquitination regulate anthrax toxin endocytosis. J Cell Biol (2006) 2.15
Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 K(ATP) channels. J Clin Invest (2002) 2.11
Anthrax lethal toxin-induced inflammasome formation and caspase-1 activation are late events dependent on ion fluxes and the proteasome. Cell Microbiol (2007) 2.09
Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu Rev Physiol (2009) 2.03
Myne-1, a spectrin repeat transmembrane protein of the myocyte inner nuclear membrane, interacts with lamin A/C. J Cell Sci (2002) 2.02
Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis (2007) 2.01
Population-based variation in cardiomyopathy genes. Circ Cardiovasc Genet (2012) 2.00
Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun (2004) 1.99
Normal myoblast fusion requires myoferlin. Development (2005) 1.97
Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am J Physiol Regul Integr Comp Physiol (2004) 1.97
Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity. Infect Immun (2004) 1.95
The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat Struct Mol Biol (2003) 1.91
Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLoS Pathog (2012) 1.90
Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J Exp Med (2005) 1.90
Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc Natl Acad Sci U S A (2003) 1.87
Disruption of nesprin-1 produces an Emery Dreifuss muscular dystrophy-like phenotype in mice. Hum Mol Genet (2008) 1.83
Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. J Am Coll Cardiol (2010) 1.83
Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Blood (2010) 1.82
Identification of the proteins required for biosynthesis of diphthamide, the target of bacterial ADP-ribosylating toxins on translation elongation factor 2. Mol Cell Biol (2004) 1.76
The genetics of dilated cardiomyopathy. Curr Opin Cardiol (2010) 1.76
Genome engineering in Bacillus anthracis using Cre recombinase. Infect Immun (2006) 1.74
Spatial localization of bacteria controls coagulation of human blood by 'quorum acting'. Nat Chem Biol (2008) 1.74
Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. J Biol Chem (2002) 1.73
Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells. Mol Cancer Ther (2004) 1.68
Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest (2009) 1.67
An antibody-based microarray assay for small RNA detection. Nucleic Acids Res (2006) 1.65
Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect Immun (2005) 1.64
Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol (2006) 1.64
Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design. Proc Natl Acad Sci U S A (2005) 1.63
LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann Neurol (2013) 1.63
Fluid support worsens outcome and negates the benefit of protective antigen-directed monoclonal antibody in a lethal toxin-infused rat Bacillus anthracis shock model. Crit Care Med (2007) 1.63
Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart. J Am Coll Cardiol (2005) 1.61
Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats. Crit Care Med (2009) 1.60
Structural and mechanistic insights into the activation of Stromal interaction molecule 1 (STIM1). Proc Natl Acad Sci U S A (2012) 1.59
Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J Immunol (2005) 1.59
Functional nitric oxide synthase mislocalization in cardiomyopathy. J Mol Cell Cardiol (2004) 1.58
Expression of Bacillus anthracis protective antigen in transgenic chloroplasts of tobacco, a non-food/feed crop. Vaccine (2004) 1.56
CA-074Me protection against anthrax lethal toxin. Infect Immun (2009) 1.55
Role of N-terminal amino acids in the potency of anthrax lethal factor. PLoS One (2008) 1.54
Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. EMBO J (2005) 1.53
Retroviral insertional mutagenesis identifies a small protein required for synthesis of diphthamide, the target of bacterial ADP-ribosylating toxins. Mol Cell (2003) 1.51
Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis (2004) 1.51
Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice. Cell Host Microbe (2010) 1.51
Susceptibility to anthrax lethal toxin-induced rat death is controlled by a single chromosome 10 locus that includes rNlrp1. PLoS Pathog (2010) 1.50
Characterization of the interaction between anthrax toxin and its cellular receptors. Cell Microbiol (2007) 1.49
Nesprin-1 mutations in human and murine cardiomyopathy. J Mol Cell Cardiol (2009) 1.48
Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 1.46
Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol Cell (2005) 1.45
The endocytic recycling protein EHD2 interacts with myoferlin to regulate myoblast fusion. J Biol Chem (2008) 1.45
Anthrax protective antigen cleavage and clearance from the blood of mice and rats. Infect Immun (2007) 1.45
Anthrax edema toxin inhibits endothelial cell chemotaxis via Epac and Rap1. J Biol Chem (2007) 1.44
Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J Biol Chem (2003) 1.43
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J Biol Chem (2007) 1.41